AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 127,400 shares, an increase of 116.7% from the December 15th total of 58,800 shares. Based on an average daily volume of 8,500 shares, the days-to-cover ratio is currently 15.0 days.
Hedge Funds Weigh In On AstraZeneca
A hedge fund recently bought a new stake in AstraZeneca stock. Eagle Bay Advisors LLC purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,001 shares of the company’s stock, valued at approximately $156,000. Institutional investors own 40.87% of the company’s stock.
AstraZeneca Trading Up 1.8 %
AZNCF stock traded up $2.37 during trading hours on Thursday, hitting $132.13. 1,869 shares of the stock traded hands, compared to its average volume of 2,770. The stock has a 50-day simple moving average of $131.35 and a 200 day simple moving average of $148.43. AstraZeneca has a one year low of $118.16 and a one year high of $175.00.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- The Role Economic Reports Play in a Successful Investment Strategy
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Insider Buying Explained: What Investors Need to Know
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
